RahulFMI's blog

The quadriplegia treatments market is projected to have a value of US$ 1,468.4 million in 2022. Based on a 4.7% compound annual growth rate (CAGR) between 2022 and 2032, quadriplegia therapy is expected to require approximately US$ 2,324.4 million worldwide by 2032.

The Quadriplegia Treatment Market is witnessing a transformative era as medical advancements and research converge to address the complexities of quadriplegia. The market is characterized by a spectrum of innovative interventions, ranging from cutting-edge therapies to assistive technologies. Rehabilitation strategies, neural regeneration initiatives, and assistive devices are contributing to a holistic approach in enhancing the quality of life for individuals grappling with quadriplegia. As scientific understanding deepens and therapeutic options diversify, the Quadriplegia Treatment Market stands at the forefront of fostering optimism and progress in the pursuit of comprehensive care for those affected by this challenging condition.

The demand for quadriplegia treatment will progressively rise, which will provide manufacturers with numerous favorable development opportunities in the near future.

Key Drivers of Quadriplegia Treatment Market

Quadriplegia is caused by spinal cord injury which is caused due to trauma at the base of the neck or skull. Some of the common causes of quadriplegia, otherwise known as tetraplegia are paralysis after any accident, tumors of the spinal cord or other spinal cord diseases. The injury to the spinal cord may cause partial or total limb paralysis.

Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-14232 

According to 2020 data sheet of Spinal Cord Injury Statistics, it was estimated that approximately 17,810 new cases of spinal cord injuries occur every year in the U.S. Some of the reasons for quadriplegia include stroke, vehicular accidents, falls, violence, sports, medical or surgical causes and others.

According to WHO statistics, published in June 2021, 20-50 million people suffer from road traffic accidents every year which lead to non-fatal injuries yet permanent disabilities to them. With the increasing rate of road traffic accidents, the demand for quadriplegia treatment is set to show a positive growth over the forecast period.

Recent technological advancements and various R&D activities in the field of quadriplegia treatment are one of the leading causes which will boost the demand for this market in forthcoming years. There is an increased level of awareness amongst the patients suffering from spinal cord injuries about various treatment options available to improve their quality of life. This is another factor which will propel the demand for various treatments for quadriplegia during the forecast market.

Electrical Stimulation: Revolutionary Technique that Got Quadriplegic People Back on their Feet.

Electrical stimulators which were originally designed to treat chronic pain helped more than a dozen patients with quadriplegia to wiggle their toes, flex their legs or even walk with support.

This was a revolutionary technique which was conducted in the lab of University of Louisville in Kentucky. Electrical stimulation thus made promising and huge gains for people with paralysis wanting to regain their functionalities. The study was published in July 2019, after which thousands of patients have enrolled in the wait lists for the electrical stimulation technique.

Elevate Strategy: Tap into Analyst Expertise Now:
https://www.futuremarketinsights.com/ask-question/rep-gb-14232 

U.S. and Canada Quadriplegia Treatment: Regional Outlook

U.S. and Canada region was found to be the largest market for the diagnosis and treatment of spinal cord injury (SCI). Increasing awareness and advanced technologies are the main drivers of this market. Most of the accidents found that alcohol was one of the most important factors; that is, approximately 25% of spinal cord injuries.

In the United States, the average annual medical cost for treating an acute spinal cord injury has been found to be in the range of $ 15,000 to $ 30,000 per year. All these factors are expected to drive the market growth of quadriplegia treatment market and offer lucrative opportunities for the providers.

Europe Quadriplegia Treatment: Regional Outlook

Europe was observed to be the second largest market, region wise for the quadriplegia treatment industry. Some of the factors contributing to this large market share are the presence of leading research institutes in the region for various neurological disease diagnosis and treatment. Increased awareness regarding various new technologies which help the quadriplegic patients lead a relatively normal life is also another key driver for this industry in Europe.

Key player:

Major manufacturers of medications needed to treat quadriplegia are

  • Merck & Co.
  • Sanofi Pharmaceuticals
  • Baxter International
  • Zydus Cadila
  • GlaxoSmithKline
  • AstraZeneca
  • Cipla
  • Johnson & Johnson
  • Bristol Myers Squibb Co.
  • Eli Lily & Co.
  • Teva Pharmaceuticals
  • Takeda Pharmaceutical Co Ltd
  • Hoffmann La Roche
  • Sun Pharmaceuticals.

In November 2020, Pfizer and Mylan announced the merger of Pfizer’s Upjohn generics unit and Mylan. This deal was a part of restructuring drive at Pfizer, which was aimed for stronger foothold in the innovative medicines division of the company.

Key Segments:

By Treatment Type:

  • Corticosteroids
  • Non- Steroidal Anti-inflammatory Drugs (NSAIDs)
  • Antidepressants
    • Selective serotonin reuptake inhibitors (SSRIs)
    • Serotonin and norepinephrine reuptake inhibitors (SNRIs)
  • Anticonvulsants
  • Narcotic Analgesics
  • Antispasmodics & Muscle Relaxants
  • Antibiotics

By Route of Administration:

  • Oral
  • Intravenous
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Stores?

a leading market intelligence and consulting firm, unveils a promising outlook for the Global Endoluminal Suturing Devices Market. According to the latest report, the market, valued at US$ 83.8 Million in 2022, is poised to surge to a remarkable US$ 295.4 Million by 2033.

The endoscopic suturing devices, holding a substantial 49.4% in terms of value share, emerged as the frontrunner in the global market within its product category in 2022. This segment is anticipated to maintain its dominance, charting an impressive growth trajectory with a Compound Annual Growth Rate (CAGR) of nearly 12.4% over the forecast period from 2023 to 2033.

The comprehensive report from Future Market Insights Inc. provides an insightful analysis of key market trends, drivers, and challenges influencing the growth of the endoluminal suturing devices market. It sheds light on the innovative technologies, regulatory landscape, and competitive strategies shaping the industry landscape.

Download the free PDF of this Report Now @
https://www.futuremarketinsights.com/reports/sample/rep-gb-7763

Key Findings from the Report:

1.     Market Valuation:The global endoluminal suturing devices market reached a valuation of US$ 83.8 Million in 2022 and is anticipated to witness an impressive surge, reaching US$ 295.4 Million by 2033.

2.     Product Leadership:Endoscopic suturing devices asserted their dominance in 2022, capturing a significant 49.4% in terms of value share. This segment is poised to continue its strong performance with a robust CAGR of close to 12.4% over the forecast period.

3.     Market Dynamics:The report delves into the dynamics influencing market growth, including emerging trends, technological advancements, and regulatory considerations. It provides a holistic view to assist stakeholders in making informed decisions.

4.     Strategic Insights:Future Market Insights Inc. offers strategic insights into market players, their competitive landscape, and key growth strategies. This includes mergers and acquisitions, product launches, and collaborations shaping the market.

"The global endoluminal suturing devices market is on a trajectory of substantial growth, fueled by technological advancements and increasing demand for minimally invasive procedures. The dominance of endoscopic suturing devices underscores the industry's commitment to innovation and patient-centric solutions. Our comprehensive report aims to guide industry stakeholders in navigating the evolving landscape and capitalizing on emerging opportunities."

Key Companies Profiled        

  • Medtronic Plc.
  • B Braun Melsungen
  • Intuitive Medical
  • Johnson & Johnson (Ethicon)
  • Richard Wolf GmbH
  • Karl Storz GmbH
  • Olympus Corporation
  • Teleflex Corporation
  • Terumo Corporation
  • Boston Scientific
  • Apollo Endosurgery
  • Cook Medical
  • Cardinal Health

Key Market Segments Covered in the Endoluminal Suturing Devices Industry Research

By Product:

  • Endoscopic Suturing Devices
  • Endovascular Suturing Devices
  • Consumables

By Application:

  • Gastrointestinal Procedures
  • Urological Procedures
  • Thoracic Procedures
  • Other Procedures

By End User:

  • Hospitals
  • Specialty Clinics
  • Independent Surgical Centers
  • Ambulatory Surgical Centers

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

 

 

Archives